No Higher Mortality Risk Including CV Death Observed with Alogliptin against Placebo: Takeda

Takeda Pharmaceutical’s dipeptidyl peptidase-4 (DPP-4) inhibitor Nesina (alogliptin) did not show a higher mortality risk including cardiovascular (CV) death against placebo in patients with type 2 diabetes, according to a post-hoc analysis from the multinational EXAMINE trial of the agent...read more